Unknown

Dataset Information

0

Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines.


ABSTRACT: Successful implementation of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines hinges on a clear understanding of the clinician-patient risk discussion (CPRD). This is a dialogue between the clinician and patient about potential for atherosclerotic cardiovascular disease risk reduction benefits, adverse effects, drug-drug interactions, and patient preferences. Designed especially for primary prevention patients, this process of shared decision making establishes the appropriateness of a statin for a specific patient. CPRD respects the autonomy of an individual striving to make an informed choice aligned with personal values and preferences. Dedicating sufficient time to high-quality CPRD offers an opportunity to strengthen clinician-patient relationships, patient engagement, and medication adherence. We review the guideline-recommended CPRD, the general concept of shared decision making and decision aids, the American College of Cardiology/American Heart Association Risk Estimator application as an implementation tool, and address potential barriers to implementation.

SUBMITTER: Martin SS 

PROVIDER: S-EPMC4760944 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines.

Martin Seth S SS   Sperling Laurence S LS   Blaha Michael J MJ   Wilson Peter W F PWF   Gluckman Ty J TJ   Blumenthal Roger S RS   Stone Neil J NJ  

Journal of the American College of Cardiology 20150401 13


Successful implementation of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines hinges on a clear understanding of the clinician-patient risk discussion (CPRD). This is a dialogue between the clinician and patient about potential for atherosclerotic cardiovascular disease risk reduction benefits, adverse effects, drug-drug interactions, and patient preferences. Designed especially for primary prevention patients, this process of shared decision making estab  ...[more]

Similar Datasets

| S-EPMC4748721 | biostudies-literature
| S-EPMC5524020 | biostudies-other
| S-EPMC8030308 | biostudies-literature
| S-EPMC8031852 | biostudies-literature
| S-EPMC5837499 | biostudies-literature
| S-EPMC4570667 | biostudies-literature
| S-EPMC8226485 | biostudies-literature
| S-EPMC8030413 | biostudies-literature
| S-EPMC8311014 | biostudies-literature
| S-EPMC9175203 | biostudies-literature